Join to View Full Profile
9609 Medical Center DrRoom 5w426Bethesda, MD 20892
Phone+1 240-276-6093
Fax+1 240-276-7892
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 10 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Little, MD is an oncologist in Bethesda, Maryland. He is currently licensed to practice medicine in Virginia.
Education & Training
University of South Carolina School of MedicineClass of 1989, MD
Certifications & Licensure
VA State Medical License 1992 - 2026
Publications & Presentations
PubMed
- 1 citationsReducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
Blood. 2025-03-27 - Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.Anna Moseley, Michael LeBlanc, Boris Freidlin, Rory M Shallis, Amer M Zeidan
Clinical Trials. 2025-01-15 - 1 citationsTolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan O'Brien
Blood Advances. 2025-01-14
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
NCI’s myeloMATCH Precision Medicine Initiative Pushes the Envelope in Myeloid Leukemia CareJanuary 3rd, 2025- NIH Launches Precision Medicine Trial for Myeloid CancersOctober 24th, 2024
- NIH Launches myeloMATCH Precision Medicine Trials for Myeloid CancersOctober 23rd, 2024
- Join now to see all
